glp-1 hypoglycemia Blockade of receptor prevents post-VSG but not injectible_hypoglycemic_drugs [TUSOM | Pharmwiki]

A composite analysis of 8 cardiovascular outcomes trials completed in 2021 demonstrated reduced incidence of major cardiovascular events by 14% and cardiovascular death by 13% (NCT01147250, NCT01179048, NCT01720446, NCT01144338, NCT02465515, NCT01394952, NCT02692716, NCT03496298)

About side effects and management: "What are the most common side effects during the first few weeks?" "How should I adjust my diet to minimize gastrointestinal side effects ?" "When should I call your office about side effects versus managing them at home?" "Are there any supplements I should take alongside this medication ?" "Could this medication interact with anything I currently take ?" Side effect questions show maturity and realism

May form clumps

Preserved inhibitory potency of GLP-1 on glucagon secretion in type 2 diabetes mellitus

Side effects Commonly reported side effects include: Nausea Constipation Diarrhea Vomiting Stomach (abdominal) pain Indigestion Headache Other potential side effects: Fatigue Belching Heartburn Bloating Hair loss Decreased appetite Gastroesophageal reflux disease Injection site reactions Most GI side effects are more common in the first few weeks and tend to ease as your body adjusts